SCHEMBL4375995

SCHEMBL4375995

CNC(=O)C1(Cc2ccccc2)CCNCC1

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 7/20 0.50
SLC6A4 P31645 7/20 0.50
SLC6A3 Q01959 7/20 0.50
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
CYP2D6 P10635 2/20 0.43
CYP3A4 P08684 1/20 0.42
HSD17B10 Q99714 1/20 0.42
ATM Q13315 1/20 0.41
SMYD3 Q9H7B4 1/20 0.41
OPRM1 P35372 2/20 0.40
SSTR4 P31391 2/20 0.40
SSTR1 P30872 1/20 0.40
TACR1 P25103 2/20 0.40
TACR3 P29371 1/20 0.40
MMP1 P03956 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31682182 0.87 SSTR4 (0.39) SLC6A2SLC6A4SLC6A3CYP2D6OPRM1
SCHEMBL4372327 0.84 SLC6A2 (0.47) SLC6A2SLC6A4SLC6A3CYP2D6ATM
SCHEMBL2172656 0.84 ATM (0.57) SLC6A2SLC6A4SLC6A3MEN1KMT2A
SCHEMBL31682199 0.83 SLC6A2 (0.53) SLC6A2SLC6A4SLC6A3MEN1KMT2A
SCHEMBL8135217 0.83 SLC6A2 (0.53) SLC6A2SLC6A4SLC6A3MEN1KMT2A
SCHEMBL1919144 0.82 SLC6A2 (0.56) SLC6A2SLC6A4SLC6A3MEN1KMT2A
SCHEMBL4632632 0.82 SLC6A2 (0.50) SLC6A2SLC6A4SLC6A3CYP2D6CYP3A4
Hydrochloric Acid SCHEMBL6543165 0.81 SLC6A2 (0.52) SLC6A2SLC6A4SLC6A3MEN1KMT2A
Hydrochloric Acid SCHEMBL5810068 0.81 SLC6A2 (0.49) SLC6A2SLC6A4SLC6A3CYP2D6CYP3A4
Hydrochloric Acid SCHEMBL8762583 0.80 LMNA (0.41) MEN1KMT2AOPRM1SSTR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101678064-B Methods of treating or preventing emesis using growth hormone secretagogues HELSINN HEALTHCARE S.A. (CH) 2016-03-16 CN disclosed
CN-101678064-A Methods of treating or preventing emesis using growth hormone secretagogues SAPPHIRE THERAPEUTICS INC 2010-03-24 CN disclosed
EP-1077941-B1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK AS (DK) 2009-08-12 EP disclosed
US-6303620-B1 USED FOR THERAPY OF MEDICAL DISORDERS RESULTING FROM A DEFICIENCY IN GROWTH HORMONE NOVO NORDISK A/S (DK) 2001-10-16 US disclosed
EP-1077941-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES Novo Nordisk A/S (DK) 2001-02-28 EP disclosed
WO-1999058501-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1999-11-18 WO disclosed